沙库巴曲缬沙坦治疗心力衰竭的新进展  

New Progress of Sacubitril/Valsartan in Treatment of Heart Failure

作　　者：刘滔 徐俊波[1,2] 吴镜[2] LIU Tao;XU Junbo;WU Jing(Zunyi Medical University,Zunyi 563003,Guizhou,China;Department of Cardiology,The Third People’s Hospital of Chengdu,Chengdu 610031,Sichuan,China)

机构地区：[1]遵义医学院,贵州遵义563003 [2]成都市第三人民医院心内科,四川成都610031

出　　处：《心血管病学进展》2018年第3期483-486,共4页Advances in Cardiovascular Diseases

摘　　要：心力衰竭是一种严重的心脏进展性疾病,其发病率、死亡率均较高。肾素-血管紧张素-醛固酮系统的过度激活在心力衰竭的病理生理学进展中起着重要作用。新型心力衰竭治疗药物沙库巴曲缬沙坦是首个血管紧张素受体-脑啡肽酶抑制剂,具有双重作用机制,在抑制脑啡肽酶的同时拮抗血管紧张素Ⅱ受体,已受到了欧美最新心力衰竭治疗指南的推荐。现对沙库巴曲缬沙坦的作用机制、临床研究、安全性及耐受性做一综述。Heart failure is a serious progressive disease with high morbidity and mortality. The hyperactivation of renin- angiotensin-aldosterone system plays an important role in the pathophysiology of heart failure. New heart failure treatment drug sacubitril/valsartan is the first-in-class angiotensin receptor neprilysin inhibitor,with dual action mechanism that is antagonistic angiotensin Ⅱ recepter while inhibiting neprilysin. The drug has been recommended by the latest guidelines for the treatment of heart failure in Europe and America. This article reviews the mechanism,clinical research,safety and tolerance of sacubitril/vvlsartan.

关 键 词：心力衰竭 药物治疗 沙库巴曲缬沙坦 血管紧张素受体-脑啡肽酶抑制剂 

分 类 号：R972.1[医药卫生—药品] R541.6[医药卫生—药学]